ATE403157T1 - Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung - Google Patents

Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung

Info

Publication number
ATE403157T1
ATE403157T1 AT05005356T AT05005356T ATE403157T1 AT E403157 T1 ATE403157 T1 AT E403157T1 AT 05005356 T AT05005356 T AT 05005356T AT 05005356 T AT05005356 T AT 05005356T AT E403157 T1 ATE403157 T1 AT E403157T1
Authority
AT
Austria
Prior art keywords
art
anp
bnp
hazards
determining
Prior art date
Application number
AT05005356T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35005597&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE403157(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE403157T1 publication Critical patent/ATE403157T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT05005356T 2004-03-15 2005-03-11 Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung ATE403157T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04006080 2004-03-15

Publications (1)

Publication Number Publication Date
ATE403157T1 true ATE403157T1 (de) 2008-08-15

Family

ID=35005597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05005356T ATE403157T1 (de) 2004-03-15 2005-03-11 Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung

Country Status (7)

Country Link
US (2) US20050239138A1 (de)
EP (1) EP1577673B1 (de)
JP (2) JP4343866B2 (de)
AT (1) ATE403157T1 (de)
CA (1) CA2500886C (de)
DE (1) DE602005008497D1 (de)
ES (1) ES2311895T3 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
EP1691200A1 (de) * 2005-02-14 2006-08-16 F. Hoffmann-La Roche Ag Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
EP1986012B1 (de) 2005-01-24 2012-06-06 F. Hoffmann-La Roche AG Verwendung von Bnp-typ für die Ermittlung von Herzversagen Risiken als Folge der Volumenüberlastung
JP4654414B2 (ja) * 2005-12-01 2011-03-23 独立行政法人産業技術総合研究所 免疫化学的検出方法、及びその検出用試薬キット
WO2007079392A2 (en) * 2005-12-30 2007-07-12 The Trustees Of Columbia University In The City Of New York Real-time assays of neuro-humoral to assess cardiovascular stress
EP1816477A1 (de) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen
MX2009000914A (es) * 2006-08-04 2009-06-18 Hannover Med Hochschule Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
ES2430290T3 (es) * 2007-03-06 2013-11-19 F. Hoffmann-La Roche Ag Utilización de péptidos de tipo PNC para predecir la necesidad de diálisis
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2011501112A (ja) * 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 心筋梗塞のモニタリング及びその治療のための手段及び方法
EP2103943A1 (de) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern
EP2133696A1 (de) 2008-06-10 2009-12-16 Eberhardt Spanuth Sehr geringe Konzentrationen von Troponin I oder T zur Beurteilung eines kardiovaskulären Risikos hinsichtlich der Verabreichung von Entzündungshemmern
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CA2846285C (en) 2011-10-17 2019-09-24 F. Hoffmann-La Roche Ag Troponin and bnp based diagnosis of risk patients and cause of stroke
CN102854321B (zh) * 2012-07-26 2015-09-02 博奥赛斯（天津）生物科技有限公司 N末端b型脑钠肽前体化学发光免疫定量检测试剂盒及其制备方法
RU2504780C1 (ru) * 2012-09-25 2014-01-20 ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ ОБРАЗОВАТЕЛЬНОЕ УЧРЕЖДЕНИЕ ВЫСШЕГО ПРОФЕССИОНАЛЬНОГО ОБРАЗОВАНИЯ "НИЖЕГОРОДСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ И СОЦИАЛЬНОГО РАЗВИТИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ГБОУ ВПО "НижГМА" МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Способ оценки риска развития неблагоприятных сердечно-сосудистых событий у пациентов с заболеваниями миокарда, подвергшихся операции с искусственным кровообращением
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
CN113571191A (zh) * 2021-08-31 2021-10-29 复旦大学附属中山医院 免疫检查点抑制剂相关mace发生风险的预测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
EP1849475A1 (de) * 1999-06-21 2007-10-31 Eli Lilly & Company Synergistische Verwendung von Thiazolidindionen mit glucagonartigem Peptid-1 und Agonisten davon zur Behandlung von nicht insulinabhängigen Diabetes
AT407580B (de) * 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
US6689083B1 (en) * 2000-11-27 2004-02-10 Chf Solutions, Inc. Controller for ultrafiltration blood circuit which prevents hypotension by monitoring osmotic pressure in blood
FI20010019A (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US6969472B2 (en) * 2001-04-19 2005-11-29 Lsi Logic Corporation Method of fabricating sub-micron hemispherical and hemicylidrical structures from non-spherically shaped templates
US7202089B2 (en) * 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
US6960472B2 (en) * 2002-11-18 2005-11-01 Ottawa Heart Institute Research Corporation Monoclonal antibodies against N-Terminus proBNP
WO2010007041A1 (en) * 2008-07-14 2010-01-21 Roche Diagnostics Gmbh Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure

Also Published As

Publication number Publication date
JP4944868B2 (ja) 2012-06-06
CA2500886A1 (en) 2005-09-15
EP1577673A1 (de) 2005-09-21
EP1577673B1 (de) 2008-07-30
US20110229907A1 (en) 2011-09-22
JP2005274569A (ja) 2005-10-06
JP4343866B2 (ja) 2009-10-14
US20050239138A1 (en) 2005-10-27
JP2009080130A (ja) 2009-04-16
CA2500886C (en) 2010-08-10
DE602005008497D1 (de) 2008-09-11
ES2311895T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
ATE403157T1 (de) Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung
Reddy et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study
Miyatani et al. Pulse wave velocity for assessment of arterial stiffness among people with spinal cord injury: a pilot study
Tomiyama et al. Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease
Tomiyama et al. Influences of age and gender on results of noninvasive brachial–ankle pulse wave velocity measurement—a survey of 12 517 subjects
Andersson et al. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study
Wilkinson et al. Increased augmentation index and systolic stress in type 1 diabetes mellitus
Ahimastos et al. Gender differences in large artery stiffness pre-and post puberty
Tatasciore et al. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension
ATE373827T1 (de) Kombination von markern für diabetes typ 1 und 2
Moran et al. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome
Arrigo et al. Soluble CD146 is a novel marker of systemic congestion in heart failure patients: an experimental mechanistic and transcardiac clinical study
Kampus et al. The relationship between inflammation and arterial stiffness in patients with essential hypertension
Scott et al. Patients with type 2 diabetes have exaggerated brachial and central exercise blood pressure: relation to left ventricular relative wall thickness
DE602005001299D1 (de) Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
Ferreira et al. Optimizing the evaluation of excess exercise ventilation for prognosis assessment in pulmonary arterial hypertension
Hasegawa et al. Aging-induced elevation in circulating complement C1q level is associated with arterial stiffness
Nalcacioglu et al. Is N-terminal pro-brain natriuretic peptide a reliable marker for body fluid status in children with chronic kidney disease?
Bilinska et al. Influence of dynamic training on hemodynamic, neurohormonal responses to static exercise and on inflammatory markers in patients after coronary artery bypass grafting
Mandalenakis et al. Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923
New et al. Free Radical–Mediated Lipid Peroxidation and Systemic Nitric Oxide Bioavailability: Implications for Postexercise Hemodynamics
Kurihara et al. Excessive alcohol intake increases the risk of arterial stiffening in men with normal blood pressure
Tomiyama et al. Elevated C-reactive protein: a common marker for atherosclerotic cardiovascular risk and subclinical stages of pulmonary dysfunction and osteopenia in a healthy population
Couppe et al. Skin autofluorescence is associated with arterial stiffness and insulin level in endurance runners and healthy controls-Effects of aging and endurance exercise
O'Donnell et al. Indexes of aortic wave reflection are not augmented in estrogen‐deficient physically active premenopausal women

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties